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TolerabilityObjective: The objective of this study was to describe a priori protocol-deﬁned analyses to evaluate the safety and
tolerability of adjunctive oral lacosamide (200–600 mg/day) in adults (ages 16–70 years) with partial-onset
seizures (POS) using data pooled from three similarly designed randomized, double-blind, placebo-controlled
trials (SP667, SP754 [NCT00136019], SP755 [NCT00220415]).
Methods: Patients with POS (≥2 years' duration, ≥2 previous antiepileptic drugs [AEDs]) uncontrolled by a stable
dosing regimen of 1–3 concomitant AEDs were randomized to treatment with lacosamide at doses of 200 mg/day,
400mg/day, or 600mg/day, or placebo. Studies comprised a 4- to 6-week titration phase to target dose followed by
a 12-weekmaintenance phase. Safety outcomes included treatment-emergent adverse events (TEAEs) of particular
relevance to patients with POS, overall TEAEs, and discontinuations due to TEAEs. Post hoc analyses included evalu-
ation of TEAEs potentially related to cognition and TEAEs leading to discontinuation analyzed by concomitant AEDs.
Results:One thousand three hundred eight patientswere randomized to and received treatment; 944 to lacosamide
and 364 to placebo.Most patients (84.4%)were taking 2 or 3 concomitant AEDs. Themost common drug-associated
TEAEs (reported by ≥5% of patients in any lacosamide dose group andwith an incidence at least twice that reported
for placebo during the treatment phase)were dizziness (30.6% for lacosamide vs 8.2% for placebo), nausea (11.4% vs
4.4%), and diplopia (10.5% vs 1.9%). Common drug-associated TEAEs generally appeared to be dose-related, and
the incidence of each was lower during the 12-week maintenance phase than during the titration phase. Most
TEAEs were either mild or moderate in intensity; severe TEAEs were predominantly observed with lacosamide
600mg/day.No individual serious TEAEoccurred in ≥1%of all lacosamide-treatedpatients. Treatment-emergent ad-
verse events led to discontinuation in 8.1%, 17.2%, and 28.6% of the lacosamide 200-, 400-, and 600-mg/day groups,
respectively (vs 4.9% of placebo). Few TEAEswere related to rash,weight loss/gain, changes in clinical chemistry pa-
rameters, or psychiatric disturbances, or were seizure-related. The odds of reporting any potential cognition-related
TEAE vs placebo increased with dose and were similar between lacosamide doses of 200 and 400 mg/day and
placebo (odds ratio 1.3, 95% conﬁdence interval 0.7–2.4). Discontinuations due to TEAEs based on most commonly
usedAEDs taken in combinationwith lacosamide (all doses combined)were carbamazepine (15.3% [51/334] vs3.9%
[5/129] placebo), lamotrigine (19.2% [56/291] vs 4.3% [5/117]), and levetiracetam (10.1% [28/278] vs 3.9% [4/103]).
Conclusions: The safety and tolerability proﬁle of adjunctive lacosamide in this detailed evaluation was similar to
that observed in the individual double-blind trials. Adjunctive lacosamide was associated with TEAEs related to
the nervous system and gastrointestinal tract, predominantly during titration.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Epilepsy Program, University of
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The antiepileptic drug (AED) lacosamide is approved at dosages up
to 400 mg/day as monotherapy or adjunctive therapy in adults
(17 years or older) with partial-onset seizures (POS) in the United
States [1] and as adjunctive therapy in adults (16 years or older) with
POS in the EuropeanUnion [2] and other countries. Lacosamide has sim-
ple pharmacokinetics for oral and intravenous administration [3–6].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with steady-state plasma levels occurring after 3 days of twice-daily
administration [3]. The pharmacokinetic parameters of lacosamide are
dose-proportional (orally administered 100–800 mg/day) and show
low intra- and intersubject variability [3]. Lacosamide is minimally
bound to plasma proteins (b15%) [4,7] and is eliminated from the
systemic circulation primarily by renal excretion [3]. Lacosamide has
shown no clinically relevant drug–drug interactions with other AEDs
[8–13], midazolam [2,14], warfarin [15], oral contraceptives [16],
omeprazole [17], digoxin [18], and metformin [19].
The safety and efﬁcacy of lacosamide as adjunctive therapy for adults
with POS have been evaluated in detail, including in three phase II/III
randomized, double-blind, placebo-controlled clinical trials and their
respective long-term open-label extension trials [10–12,20,21]. Results
from these pivotal double-blind trials demonstrated that adjunctive
lacosamide signiﬁcantly reduced the frequency of POS in patients with
epilepsy and was associated with an acceptable safety proﬁle [10–12].
However, the evaluation of drug safety is a continuous process and
depends on input from various sources, including standard registration
trials, long-term extension studies, observational studies, and safety
monitoring efforts. Pooled data analyses from multiple clinical trials
are another means to assess drug safety.
The three double-blind lacosamide trials had similar study designs
and patient populations, thus, allowing a valuable opportunity for data
pooling. The pooling of data from the three trials facilitates a more
detailed evaluation of treatment effect than that from individual trials.
Efﬁcacy analyses on pooled data are published [22], conﬁrming and
extending the results of the individual trials. Notably, adjunctive
lacosamide signiﬁcantly reduced overall seizure frequency compared
with placebo treatment, regardless of concomitant AEDs or patients' ep-
ilepsy surgical history [22]. An additional post hoc analysis suggested
that adjunctive lacosamide treatment demonstrated seizure reduction
compared with placebo regardless of the inclusion of “traditional”
sodium channel blockers, which were included in the concomitant
AED regimen of 82% of patients [23]. This post hoc analysis also showed
that lacosamide was well tolerated by most patients taking either
sodium channel-blocking AEDs or nonsodium channel-blocking AEDs
and suggested that lacosamide may have potential for improved tolera-
bility when added to an AED regimen that did not include traditional
sodium channel blockers, especially at higher lacosamide doses [23].SP667 [10]
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Fig. 1. Design of the double-blind, placebo-controlled clinical trials of lacosamide for the adjunc
allowed at the end of titration in cases of intolerable adverse events. PBO, placebo; LCM, lacosa
Modiﬁed from Chung S. et al. [22].Here, we present the results of a priori protocol-deﬁned and post hoc
safety analyses of data pooled from the three pivotal double-blind,
placebo-controlled lacosamide trials. Though data have been reported
elsewhere [22–24], the current analyses go beyond previous reports to
provide a more detailed description of the safety proﬁle of lacosamide,
including additional safety information of particular interest, such as
rash, psychiatric effects, seizure-related adverse events (AEs), weight
change, and clinical laboratory changes. In addition, post hoc analyses
investigated AEs potentially related to cognition and AEs leading to
discontinuation analyzed by concomitant AEDs.
2. Methods
2.1. Trial design
Safety analyses were performed on data pooled from three similarly
designed randomized, double-blind, placebo-controlled trials (SP667
[10], SP754 [NCT00136019] [11] and SP755 [NCT00220415] [12]) that
evaluated the safety and efﬁcacy of adjunctive lacosamide treatment
in adults with uncontrolled POS. The SP667 trial was conducted in
Europe and the United States, SP754 in the United States, and SP755
in Europe and Australia. Detailed methods are published elsewhere
[10–12]. All studies were conducted in accordance with the Declaration
of Helsinki. The trial protocol, amendments, and informed consent
documentation were reviewed by national regulatory authorities in
each country and relevant ethics committees or Institutional Review
Boards for each site. Before trial participation, all patients gave written
informed consent.
In each trial, patients were randomized to receive ﬁxed dosages of
lacosamide or placebo twice-daily in equally divided doses (Fig. 1). In
all trials, a single 100 mg/day dose reduction was allowed at the end
of the titration phase for patients experiencing intolerable AEs.
2.2. Patient eligibility
Patients aged 16–70 years (18–65 years in SP667) with a diagnosis
of focal epilepsy and who had experienced POS (with or without
secondary generalization) for 2 years or longer despite therapy with
two or more AEDs (concurrently or sequentially) were recruited. To
be eligible for randomization, patientswere required to have an average1:1:1:1
PBO :LCM 200 :LCM 400 :LCM 600
1:2:1
PBO : LCM 400 : LCM 600
1:1:1
PBO : LCM 200 : LCM 400
Maintenance
12 weeks
Transition/ 
Taper
2-3 weeks
tment Period
tive treatment of adults with partial-onset seizures. One back-titration of 100 mg/day was
mide.
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secondarily generalized seizures) per 28 days, with seizure-free periods
lasting no longer than 21 days, in the 8 weeks prior to baseline and
during the 8-week baseline period. Patients had to be receiving a stable
dosing regimen of 1–3 concomitant AEDs (no more than two in SP667)
with or without vagus nerve stimulation for at least 4 weeks prior to
baseline and throughout the trial.
2.3. Safety assessments
Safety variables were treatment-emergent adverse events (TEAEs) as
reported during the titration, maintenance, and treatment (titration +
maintenance) phases, serious TEAEs (SAEs; those TEAEs that were fatal
or life-threatening, required or prolonged hospitalization, were a con-
genital anomaly/birth defect, or were considered to be an important
medical event that may have jeopardized the patient or put them at
risk), and TEAEs leading to discontinuation. In addition, TEAE severity
(intensity, which ranged from mild [did not interfere with routine
activities] to severe [subject was unable to perform routine activities])
and relationship to trial medication, as judged by the investigator,
were also evaluated.
The deﬁnition of a TEAE used in the trials was consistent with the
International Conference on Harmonisation of Technical Requirements
for Registration of Pharmaceuticals for Human Use (ICH) guidelines.
The TEAEs (observed by the investigator or reported by the patient to
the investigator) were collected at each clinical visit and were coded
according toMedical Dictionary for Regulatory Activities (MedDRA, ver-
sion 9.1) preferred terms and the corresponding primary system organ
class. In order to standardize investigator evaluation of safety among
sites and trials, standard assessments were described for seriousness,
intensity, outcome, and causality. An AE was deﬁned as treatment-
emergent if it started on or after the date of the ﬁrst dose of trial
medication. A TEAE that ﬁrst occurred during the titration phase
(whether or not it persisted throughout the maintenance phase) was
included only for the incidence of TEAEs during the titration phase,
while a TEAE that occurred only during the maintenance phase was in-
cluded only for the incidence of TEAEs during this phase. If a TEAE
started during the titration phase, resolved in the maintenance phase,
and then reemerged as a new event during maintenance phase, the
event was included in the TEAE incidence for both phases.
To further evaluate TEAEs associatedwith lacosamide, common drug-
associated TEAEswere deﬁned as those reported by ≥5% of patients in any
lacosamide dose group andwith an incidence at least twice that reported
for placeboduring the treatment phase. The TEAEs related to rash, psychi-
atric disturbances (psychosis, depression, and suicide), weight change,
cognition, or seizures were also assessed. Laboratory parameters, ECGs,
vital signs, and body weight were also monitored.
2.4. Data analyses
Pooled analyses of safety variables were performed on the safety
set, which included all patients who took at least one dose of trial
medication (lacosamide or placebo) during one of the three double-
blind trials. Results were summarized using descriptive statistics.
For the evaluation of TEAEs related to rash, the following four
MedDRA preferred terms were evaluated: rash, rash pruritic, rash gen-
eralized, and rashmaculopapular. For the assessment of select psychiat-
ric events, the following threeMedDRA preferred termswere evaluated
for TEAEs related to psychosis: psychotic disorder, epileptic psychosis,
and acute psychosis. The following three MedDRA preferred terms
were evaluated for TEAEs related to suicide: suicidal ideation, suicide at-
tempt, and completed suicide. The MedDRA preferred term depression
was analyzed separately. For TEAEs related to seizure, the following 10
MedDRA preferred terms were examined: convulsion, grand mal
convulsion, epilepsy, aura, epileptic aura, simple partial seizures, com-
plex partial seizures, partial seizures, myoclonus, and status epilepticus.For TEAEs potentially related to cognition, the following 17MedDRA
preferred terms were identiﬁed: memory impairment, cognitive disor-
der, confusional state, disturbance in attention, mental impairment,
lethargy, bradyphrenia, amnesia, mental status changes, disorientation,
aphasia, depressed level of consciousness, communication disorder, dis-
sociation, speech disorder, dysphasia, and reading disorder. As testing
group differences for these speciﬁc terms was not prespeciﬁed in the
studies, a post hoc analysis comparing treatment to placebo was per-
formed to evaluate this broad range of terms. The incidence of individ-
ual TEAEs was calculated for each lacosamide dose group (combined
and separate) and for placebo, and the odds of experiencing any
TEAEs identiﬁed as cognition-related were evaluated using a logistic
regression model with adjustment for trial.
An analysis was also performed to evaluate TEAEs that led to discon-
tinuation, according to concomitant AED use. In this analysis, patients
could be assigned to as many as three different subgroups (one for
each concomitant AED taken). The TEAEs that led to discontinuation
were assessed for all lacosamide doses combined and for placebo.
3. Results
3.1. Demographic and baseline characteristics in the pooled patient
population
The pooled safety population included 1308 patients who received
at least one dose of trialmedication during the double-blind trials (safe-
ty set; Fig. 2). Of these patients, 944 received lacosamide (200 mg/day,
n=270; 400mg/day, n=471; 600mg/day, n=203) and 364 received
placebo. Mean age was 38.6 ± 11.79 years, and there was an even dis-
tribution of men (49.0%) and women (51.0%) (Table 1). Of 1308 pa-
tients, 587 (44.9%) had lifetime use of ≥7 AEDs; most patients (84.4%)
were taking 2–3 concomitant AEDs, primarily carbamazepine (35.4%),
lamotrigine (31.2%), and levetiracetam (29.1%) (groups not mutually
exclusive). Patients experienced a median of 11.5 seizures per 28 days
during the 8-week baseline.
3.2. Patient disposition
Most patients (78.5%) completed the trial in which they enrolled.
Among patients assigned to lacosamide, completer rates were 81.9%
(200mg/day), 77.1% (400mg/day), and 61.2% (600mg/day), compared
with 87.1% of patients assigned to placebo (Fig. 2). The percentage of
patients discontinuing from the trial because of AEs increased with
increasing lacosamide dose (9.6% for lacosamide 200 mg/day, 17.2%
for 400 mg/day, and 28.6% for 600 mg/day); in the placebo group,
5.2% of patients discontinued because of AEs. Other reasons for discon-
tinuation (lack of efﬁcacy, withdrew consent, protocol deviation, poor
compliance, and lost to follow-up) occurred at similar rates across
lacosamide and placebo treatments. Of 1308 patients in the safety
set, 1054 (80.6%) enrolled in the subsequent lacosamide open-label
extension trials.
3.3. Overall incidence of TEAEs
During the treatment phase (titration + maintenance), the overall
incidence of any TEAE was 81.0% for all lacosamide doses combined
(vs 64.6% for placebo) and appeared to be dose-related (69.6% for
200 mg/day, 82.2% for 400 mg/day, and 93.6% for 600 mg/day).
Among all patients who received lacosamide, the most frequently re-
ported TEAEs (occurring at an incidence of ≥10%) were dizziness
(30.6% vs 8.2% for placebo), headache (12.7% vs 8.8%), nausea (11.4%
vs 4.4%), and diplopia (10.5% vs 1.9%). Of these, dizziness, nausea,
and diplopia were among those considered drug-associated TEAEs
(occurring in ≥5% of patients in any lacosamide treatment group and
at least twice as often as in the placebo group; Table 2). Common
drug-associated TEAEs were most commonly associated with the
SP667 (safety set)
N = 418
SP754 (safety set)
N = 405
SP755 (safety set)
N = 485
Analyzed for safety in pooled analysis
N = 1308
Placebo
n = 364
Lacosamide 200 mg/day
n = 270
Lacosamide 400 mg/day
n = 471
Lacosamide 600 mg/day
n = 203
Discontinued n = 47
Adverse event 19
Lack of efficacy 5
Withdrew consent 12
Protocol deviation 5
Poor compliance 3
Lost to follow-up 5
Other 2
Completed 87.1%
(n = 317)
Discontinued n = 49
Adverse event 26
Lack of efficacy 3
Withdrew consent 11
Protocol deviation 3
Poor compliance 4
Lost to follow-up 1
Other 2
Discontinued n = 108
Adverse event 81
Lack of efficacy 3
Withdrew consent 14
Protocol deviation 4
Poor compliance 7
Lost to follow-up 0
Other 3
Discontinued n = 77
Adverse event 58
Lack of efficacy 2
Withdrew consent 9
Protocol deviation 5
Poor compliance 3
Lost to follow-up 0
Other 1
Completed 81.9%
(n = 221)
Completed 77.1%
(n = 363)
Completed 62.1%
(n = 126)
Fig. 2. Patient disposition in the pooled analysis of double-blind, placebo-controlled clinical trials of lacosamide for the adjunctive treatment of adults with partial-onset seizures.
Modiﬁed from Chung S. et al. [22].
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Incidence of TEAEs considered by the investigator to be related to trial
medication was 61.1% for lacosamide overall and increased withTable 1
Demographic and baseline characteristics of patients participating in double-blind, placebo-con
seizures (safety set).
Placebo (n = 364) Adjunctive lacosam
200 mg/day (n = 2
Age (mean ± SD, years) 38.5 ± 11.25 38.1 ± 11.78
Female, n (%) 177 (48.6) 134 (49.6)
Time since diagnosis, (mean ± SD, years)a 23.3 ± 12.56 23.7 ± 12.56
Lifetime AEDs, n (%)
1–3 80 (22.0) 62 (23.0)
4–6 121 (33.2) 84 (31.1)
≥7 160 (44.0) 120 (44.4)
Missing 3 (0.8) 4 (1.5)
Number of concomitant AEDs, n (%)
1 62 (17.0) 34 (12.6)
2 214 (58.8) 168 (62.2)
3b 88 (24.2) 68 (25.2)
Most commonc concomitant AEDs, n (%)
Carbamazepine 129 (35.4) 115 (42.6)
Lamotrigine 117 (32.1) 70 (25.9)
Levetiracetam 103 (28.3) 70 (25.9)
Valproate 95 (26.1) 74 (27.4)
Topiramate 83 (22.8) 70 (25.9)
Median baseline seizure frequency per 28 daysd 11.0 12.2
AEDs, antiepileptic drugs.
a n = 470 for 400 mg/day, 202 for 600 mg/day, and 1306 for total population.
b Trial SP667 did not allow patients taking three concomitant AEDs.
c Represents the ﬁve most commonly used concomitant AEDs.
d n = 359 for placebo, 267 for 200 mg/day, 469 for 400 mg/day, 202 for 600 mg/day, and 1increasing lacosamide dose: 44.1% for lacosamide 200 mg/day, 62.8%
for lacosamide 400 mg/day, and 79.8% for lacosamide 600mg/day, com-
pared with 38.7% for placebo. For the approved lacosamide dose rangetrolled clinical trials of lacosamide for the adjunctive treatment of adults with partial-onset
ide Total population (N = 1308)
70) 400 mg/day (n = 471) 600 mg/day (n = 203)
39.2 ± 12.44 38.1 ± 11.18 38.6 ± 11.79
245 (52.0) 111 (54.7) 667 (51.0)
24.0 ± 13.14 23.5 ± 12.97 23.7 ± 12.82
112 (23.8) 32 (15.8) 286 (21.9)
151 (32.1) 68 (33.5) 424 (32.4)
205 (43.5) 102 (50.2) 587 (44.9)
3 (0.6) 1 (0.5) 11 (0.8)
78 (16.6) 30 (14.8) 204 (15.6)
281 (59.7) 151 (74.4) 814 (62.2)
112 (23.8) 22 (10.8) 290 (22.2)
150 (31.8) 69 (34.0) 463 (35.4)
159 (33.8) 62 (30.5) 408 (31.2)
147 (31.2) 61 (30.0) 381 (29.1)
99 (21.0) 40 (19.7) 308 (23.5)
106 (22.5) 32 (15.8) 291 (22.2)
11.0 13.5 11.5
297 for total population.
Table 2
Incidence of common drug-associated TEAEsa during the treatment phase (titration and
maintenance) in double-blind, placebo-controlled clinical trials of lacosamide for the ad-
junctive treatment of adults with partial-onset seizures (safety set).
MedDRA
preferred term
Placebo
(n = 364)
Adjunctive lacosamide
200 mg/day
(n = 270)
400 mg/day
(n = 471)
600 mg/day
(n = 203)
All doses of
lacosamide
(n = 944)
Dizziness 30 (8.2) 43 (15.9) 139 (29.5) 107 (52.7) 289 (30.6)
Nausea 16 (4.4) 20 (7.4) 53 (11.3) 35 (17.2) 108 (11.4)
Diplopia 7 (1.9) 17 (6.3) 49 (10.4) 33 (16.3) 99 (10.5)
Vomiting 9 (2.5) 16 (5.9) 40 (8.5) 32 (15.8) 88 (9.3)
Fatigue 21 (5.8) 19 (7.0) 34 (7.2) 30 (14.8) 83 (8.8)
Vision blurred 9 (2.5) 6 (2.2) 40 (8.5) 33 (16.3) 79 (8.4)
Ataxiab 6 (1.6) 11 (4.1) 34 (7.2) 31 (15.3) 76 (8.1)
Tremor 15 (4.1) 10 (3.7) 29 (6.2) 24 (11.8) 63 (6.7)
Nystagmus 14 (3.8) 6 (2.2) 21 (4.5) 21 (10.3) 48 (5.1)
Balance disorder 0 (0) 3 (1.1) 24 (5.1) 13 (6.4) 40 (4.2)
Memory
impairment
6 (1.6) 3 (1.1) 7 (1.5) 12 (5.9) 22 (2.3)
MedDRA, Medical Dictionary for Regulatory Activities.
For each TEAE, data are presented as n (%) of patients experiencing the TEAE at least once.
a Common drug-associated TEAEs deﬁned as those TEAEs occurring in ≥5% of patients
in any lacosamide treatment group and at least twice as often as in the placebo group.
b Reported as coordination abnormal.
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≥10% were dizziness (24.6%) and headache (12.8%).3.4. Intensity of TEAEs
Most patients who received lacosamide reported TEAEs with a maxi-
mum intensity of mild (32.2%) or moderate (38.3%) (vs placebo: 38.5%
mild, 21.4% moderate). Severe TEAEs were reported by 10.4% of patients
in the lacosamide group, and 4.7% of those receiving placebo. Incidences
of severe TEAEs were similar in the lacosamide 200 mg/day (7.0%) and
400 mg/day (9.1%) groups, but increased with lacosamide 600 mg/day
(17.7%). The most frequently reported severe common drug-associated
TEAE overall was dizziness (3.7% for lacosamide vs 0% for placebo) and
increased across the lacosamide dose range (1.9% for 200 mg/day, 2.3%
for 400mg/day, and 9.4% for 600mg/day). Incidence of all other common
drug-associated TEAEs rated as severe did not increase in a dose-
dependent manner.Table 3
Incidence of commondrug-associated TEAEsa separated into the titration andmaintenance pha
ment of adults with partial-onset seizures (safety set).
MedDRA preferred term Titration phase
Placebo
(n = 364)
Adjunctive lacosamide (mg/day)
200
(n = 270)
400
(n = 471)
600
(n = 203)
A
(
Dizziness 24 (6.6) 28 (10.4) 116 (24.6) 96 (47.3) 2
Nausea 13 (3.6) 15 (5.6) 40 (8.5) 33 (16.3)
Diplopia 4 (1.1) 12 (4.4) 39 (8.3) 30 (14.8)
Vomiting 7 (1.9) 13 (4.8) 29 (6.2) 30 (14.8)
Fatigue 19 (5.2) 18 (6.7) 32 (6.8) 23 (11.3)
Vision blurred 6 (1.6) 5 (1.9) 29 (6.2) 30 (14.8)
Ataxiab 5 (1.4) 6 (2.2) 28 (5.9) 28 (13.8)
Tremor 12 (3.3) 4 (1.5) 20 (4.2) 22 (10.8)
Nystagmus 11 (3.0) 4 (1.5) 19 (4.0) 16 (7.9)
Balance disorder 0 (0) 2 (0.7) 17 (3.6) 8 (3.9)
Memory impairment 5 (1.4) 2 (0.7) 6 (1.3) 7 (3.4)
MedDRA, Medical Dictionary for Regulatory Activities.
For each TEAE, data are presented as n (%) of patients experiencing the TEAE at least once during
during that phase.
a Common drug-associated TEAEs deﬁned as those TEAEs occurring in ≥5% of patients in any l
placebo group.
b Coordination abnormal.3.5. TEAEs during titration vs maintenance
Overall, 68.3% of patients in the lacosamide group and 53.3% of
placebo patients reported at least one TEAE during the titration phase
(4–6 weeks, depending on study). The incidence of TEAEs during
the titration phase increased with increasing lacosamide dose:
51.1% for lacosamide 200 mg/day, 69.9% for 400 mg/day, and 87.7% for
600 mg/day. During the maintenance phase, at least one TEAE was re-
ported by 60.2% (470/781) of patients who received lacosamide during
the phase and 44.5% (150/337) of those who received placebo during
the phase. Incidence of TEAEs during the maintenance phase was
generally similar across lacosamide dose groups (54.9% [135/246] for
200 mg/day, 62.3% [245/393] for 400 mg/day, and 63.4% [90/142] for
600 mg/day). The incidence of the most common drug-associated
TEAEs was lower during the maintenance phase than during the titra-
tion phase for patients in the lacosamide group (Table 3).
3.6. Serious TEAEs during treatment
One deathwas reported in the double-blind trials. This male patient,
who was randomized to lacosamide 200 mg/day, reported depression
(due to spouse's illness), which was recorded as a nonserious TEAE
(rated severe) 3 weeks prior to death (suicide) and was not considered
by the investigator to be related to the trialmedication. The incidence of
other SAEs was higher among all patients who received lacosamide
(6.5%) than placebo (3.8%). No overall dose effect was observed across
the lacosamide treatment groups for SAEs (7.8% for 200 mg/day, 7.2%
for 400 mg/day, and 3.0% for 600 mg/day). The most frequently report-
ed SAEs (≥1% of patients in any lacosamide treatment group) were con-
vulsion, dizziness, and nystagmus. Cases of convulsion that met criteria
for SAEs were reported by 0.8% of patients who received lacosamide (vs
0.8% placebo), with a similar incidence across lacosamide doses (1.1%
for 200 mg/day, 1.1% for 400 mg/day, and 0% for 600 mg/day). Cases
of dizziness and nystagmus that were identiﬁed as SAEs occurred only
in the lacosamide 600 mg/day group (1.5% for dizziness and 1.0% for
nystagmus).
3.7. TEAEs leading to discontinuation
During the treatment phase, TEAEs led to discontinuation in 17.1% of
patients in the lacosamide group (8.1%, 17.2%, and 28.6% for lacosamide
200, 400, and 600 mg/day groups, respectively; Table 4) and in 4.9% ofses in double-blind, placebo-controlled clinical trials of lacosamide for the adjunctive treat-
Maintenance phase
Placebo
(n = 364)
Adjunctive lacosamide (mg/day)
ll doses
n = 944)
200
(n = 270)
400
(n = 471)
600
(n = 203)
All doses
(n = 944)
40 (25.4) 6 (1.8) 18 (7.3) 33 (8.4) 14 (9.9) 65 (8.3)
88 (9.3) 4 (1.2) 5 (2.0) 17 (4.3) 4 (2.8) 26 (3.3)
81 (8.6) 3 (0.9) 9 (3.7) 14 (3.6) 3 (2.1) 26 (3.3)
72 (7.6) 3 (0.9) 10 (4.1) 16 (4.1) 5 (3.5) 31 (4.0)
73 (7.7) 2 (0.6) 3 (1.2) 5 (1.3) 7 (4.9) 15 (1.9)
64 (6.8) 3 (0.9) 3 (1.2) 12 (3.1) 4 (2.8) 19 (2.4)
62 (6.6) 1 (0.3) 6 (2.4) 7 (1.8) 8 (5.6) 21 (2.7)
46 (4.9) 3 (0.9) 6 (2.4) 9 (2.3) 2 (1.4) 17 (2.2)
39 (4.1) 3 (0.9) 2 (0.8) 2 (0.5) 5 (3.5) 9 (1.2)
27 (2.9) 0 (0) 2 (0.8) 8 (2.0) 5 (3.5) 15 (1.9)
15 (1.6) 1 (0.3) 1 (0.4) 1 (0.3) 5 (3.5) 7 (0.9)
the respective phase, based on the number of subjectswith at least one dose administered
acosamide treatment groupduring the treatment phase and at least twice as often as in the
Table 4
Incidence of TEAEs leading to discontinuationa during the treatment phase (titration and
maintenance) in double-blind, placebo-controlled clinical trials of lacosamide for the ad-
junctive treatment of adults with partial-onset seizures (safety set).
MedDRA
preferred term
Placebo
(n = 364)
Adjunctive lacosamide
200 mg/day
(n = 270)
400 mg/day
(n = 471)
600 mg/day
(n = 203)
All doses of
lacosamide
(n = 944)
Any event 18 (4.9) 22 (8.1) 81 (17.2) 58 (28.6) 161 (17.1)
Dizziness 2 (0.5) 1 (0.4) 20 (4.2) 35 (17.2) 56 (5.9)
Ataxiab 0 (0) 1 (0.4) 6 (1.3) 11 (5.4) 18 (1.9)
Vomiting 1 (0.3) 1 (0.4) 11 (2.3) 6 (3.0) 18 (1.9)
Diplopia 1 (0.3) 4 (1.5) 10 (2.1) 4 (2.0) 18 (1.9)
Nausea 1 (0.3) 1 (0.4) 8 (1.7) 8 (3.9) 17 (1.8)
Vertigo 0 (0) 3 (1.1) 4 (0.8) 5 (2.5) 12 (1.3)
Vision blurred 0 (0) 1 (0.4) 3 (0.6) 6 (3.0) 10 (1.1)
Tremor 0 (0) 0 (0) 3 (0.6) 5 (2.5) 8 (0.8)
Nystagmus 0 (0) 0 (0) 1 (0.2) 5 (2.5) 6 (0.6)
MedDRA, Medical Dictionary for Regulatory Activities.
For each TEAE, data are presented as n (%) of patients discontinuing because of the TEAE.
a Data presented for TEAEs leading to discontinuation of ≥2% of patients in any lacosamide
dose group.
b Coordination abnormal.
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were the only two TEAEs that individually led to N5% of patients
discontinuing from any lacosamide dose group. Discontinuations due
to dizziness increased with increasing lacosamide dose (0.4%, 4.2%,
and 17.2% for lacosamide 200, 400, and 600 mg/day, respectively, vs
0.5% for placebo).
Discontinuations due to TEAEs according to the presence of each of
the most commonly used AEDs as one of the concomitant AEDs in
the combination therapy were: carbamazepine (15.3% [51/334] for
lacosamide pooled doses vs 3.9% [5/129] for placebo), lamotrigine
(19.2% [56/291] vs 4.3% [5/117]), levetiracetam (10.1% [28/278] vs
3.9% [4/103]), valproate (15.5% [33/213] vs 1.1% [1/95]), and topiramate
(11.5% [24/208] vs 3.6% [3/83]) (note: 84.4% of patients took lacosamide
in combinationwithmore than one other AED; discontinuations report-
ed here are not mutually exclusive for each AED).
SAEs led to discontinuation during the treatment phase by 2.9% of
patients receiving lacosamide and 0.8% of those receiving placebo. The
SAEs that most commonly led to discontinuation in lacosamide-
treated patients were dizziness (0.3%) and convulsion (0.3%).
3.8. Other TEAEs of interest
Based on safety data from the double-blind trials and safety consid-
erations for AEDs in general, additional TEAEswere identiﬁed a priori for
evaluation. These TEAEs are of particular relevance to patients with POS
taking AEDs.
3.8.1. Rash
The incidence of rash was similar for patients in the lacosamide
group (n = 27, 2.9%) and those receiving placebo (n = 11, 3.0%),
and was consistent across lacosamide dose groups (n = 4 [1.5%]
for 200 mg/day, n = 16 [3.4%] for 400 mg/day, n = 34 [3.4%] for
600 mg/day). Incidence of rash was similar in the titration phase
(2.0% of patients in the lacosamide group and 1.6% of the placebo
group) and maintenance phase (1.2% of lacosamide patients and
1.5% of placebo patients). In addition, one patient experienced rash
pruritic (lacosamide 600 mg/day) during the titration phase, and
one patient experienced rash generalized (lacosamide 400 mg/day)
during the maintenance phase; rash maculopapular was experienced
by one patient in the placebo group. None of these rash events was
considered serious, and no TEAE of Stevens–Johnson Syndrome or
toxic epidermal necrolysis was reported. Among the 41 patients
reporting a rash-related TEAE, the TEAE was considered by the inves-
tigator to be related to trial medication in eight (0.8%) lacosamidepatients and in six (1.6%) placebo patients. Rash led to premature
discontinuation from the trial by two (0.2%) lacosamide-treated
patients and two (0.5%) placebo patients.
3.8.2. Select psychiatric events
Three patients who received lacosamide (0.3%) experienced a TEAE
related to psychosis: one epileptic psychosis and two psychotic disor-
ders. All three patients received lacosamide 400 mg/day, and all three
TEAEs were considered serious. One of the cases of psychotic disorder
was considered related to trial medication and led to discontinuation.
No TEAE was related to psychosis in the placebo group.
The incidence of irritability was 1.5% in patients in the lacosamide
group and 1.1% of placebo patients which is well below the threshold
for reporting here but is of general interest.
Six patients randomized to lacosamide experienced events rated as
suicidality-related in this population. Among these six cases, four
(4/944; 0.4%) were reported to be receiving lacosamide at the time of
the event, and two were not receiving the study drug at the time of
event onset. One of the six patients represented a completed suicide
(described in Section 3.6), while the remaining ﬁve patients were
rated as suicidal ideation. No TEAE was related to suicidality in the
placebo group.
Depression was reported by 20 (2.1%) patients randomized
to lacosamide (six [2.2%] in the 200 mg/day group, 11 [2.3%] in the
400 mg/day group, three [1.5%] in the 600 mg/day group) and by two
patients (0.5%) receiving placebo.
3.8.3. Seizure-related TEAEs
Seizure-related TEAEs were reported by 46 (4.9%) patients who re-
ceived lacosamide and by 19 (5.2%) who received placebo. The most
common seizure-related TEAE was convulsion, which was reported
with a similar incidence for lacosamide (3.9%) and placebo (3.6%).
Serious seizure-related TEAEs were reported by 13 (1.4%) patients
who received lacosamide and by seven (1.9%) who received placebo.
The most common serious seizure-related TEAE was convulsion,
which occurred with a similar incidence in the lacosamide and placebo
groups (0.8% for both). One SAE of status epilepticuswas reported in the
lacosamide 400 mg/day group, which resulted in the patient's discon-
tinuation from the trial. There were a few discontinuations due to a
seizure-related TEAE (12 [1.3%] patients who received lacosamide and
six [1.7%] who received placebo); the seizure-related TEAE most
frequently leading to discontinuation from the trial was convulsion
(10 [1.1%] patients who received lacosamide and four [1.1%] who
received placebo).
3.8.4. Body weight
A TEAE of weight increase was reported by 11 (1.2%) patients
randomized to lacosamide (two patients in the 200 mg/day group,
seven in the 400 mg/day group, two in the 600 mg/day group)
and two (0.5%) in the placebo group. One patient in the lacosamide
400 mg/day group discontinued because of a TEAE of weight increase.
Ten (1.1%) lacosamide-treated patients (two patients in the 200 mg/day
group, four in the 400 mg/day group, and four in the 600 mg/day
group) reported a TEAE of weight decrease, compared with three (0.8%)
in the placebo group. One patient in the lacosamide 200 mg/day group
discontinued because of a TEAE of weight decrease. No patient reported
a SAE of increase or decrease in weight.
Mean (SD) changes in body weight during the treatment phase,
measured as part of the vital signs assessment, were similar across
lacosamide dose groups (+0.2 (2.7) kg for 200 mg/day, 0.0 (2.9) kg
for 400 mg/day, +0.2 (3.6) kg for 600 mg/day vs +0.3 (2.6) kg for
placebo). The proportion of patients exhibiting a ≥10% increase in
body weight was similar between lacosamide (1.1%) and placebo
(1.4%) groups, and was similar across lacosamide doses groups (1.5%
for 200 mg/day, 0.6% for 400 mg/day, 1.0% for 600 mg/day). A decrease
in bodyweight of ≥10% during the treatment phasewas experienced by
125V. Biton et al. / Epilepsy & Behavior 52 (2015) 119–1271.5% of patients who received lacosamide and 1.4% of placebo pa-
tients, and was also similar across lacosamide dose groups (1.5% for
200 mg/day, 1.5% for 400 mg/day, 2.0% for 600 mg/day).
3.8.5. Post hoc analysis of TEAEs potentially related to cognition
The overall incidence of TEAEs identiﬁed as potentially related to
cognition (see Section 2.4)was 7.7% for lacosamide and 4.7% for placebo
(odds ratio [OR] 1.6, 95% conﬁdence interval [CI] 0.9–2.8). The odds
of reporting any potential cognition-related TEAE vs placebo increased
with dose: 200 mg/day (incidence 1.9%) OR 0.4, 95% CI 0.1–1.2;
400 mg/day (incidence 8.5%) OR 1.7, 95% CI 1.0–3.1; 600 mg/day
(incidence 13.8%) OR 2.8, 95% CI 1.3–5.7. Within the approved
dose range (200 mg/day and 400 mg/day dose groups combined),
the incidence of these cognition-related TEAEs was 6.1%, and was
similar to placebo (OR 1.3, 95% CI 0.7–2.4). All individual TEAEs
potentially related to cognition occurred with an incidence of
b2% in the 200 mg/day and 400 mg/day groups, with the exception
of cognitive disorder, which was reported by 2.1% of patients in
the 400 mg/day group (Table 5).
3.9. Clinical chemistry values and vital signs
Abnormal clinical chemistry values reported as TEAEs that occurred
with the highest incidence during the treatment phase were hypercho-
lesterolemia (1.1% lacosamide vs 0.3% placebo), hyponatremia (0.6%
lacosamide vs 0.3% placebo), increased gamma-glutamyl transferase
(0.8% lacosamide vs 0.3% placebo) and increased blood triglycerides
(0.6% lacosamide vs 0.5% placebo). Treatment-emergent elevations
of alanine aminotransferase to ≥3 times the upper limit of normal
occurred in 0.5% of lacosamide-treated patients and in 0% of placebo pa-
tients. No patient in any treatment group had amaximum total bilirubin
value ≥2 times the upper limit of normal. The TEAE of liver function test
abnormal was reported by three lacosamide patients (0.3%).
Six lacosamide-treated patients discontinued the study because
of TEAEs related to abnormal clinical chemistry values. One patient
(200 mg/day) withdrew from the study because of liver function test ab-
normality, three because of elevated liver enzymes (two on 200 mg/day,
one on 400 mg/day), and two because of hyponatremia (one each on
400 mg/day and 600 mg/day). No discontinuations due to abnormal
clinical chemistry values were reported in the placebo group.
All mean/median values for hematology parameters for patients
receiving lacosamide remained within the normal range and were not
different from the placebo group. There were no consistent trends or
changes from baseline for any hematology parameters considered to
be related to lacosamide treatment.
Mean changes in blood pressure and pulse rate wereminimal across
all lacosamide treatment groups and were similar to the placebo group.
Similarly, no clinically relevant changes for any additional vital sign
parameters considered likely to be related to lacosamide treatment
were observed.Table 5
TEAEs potentially related to cognitiona during the treatment phase of double-blind, placebo-con
seizures (safety set).
MedDRA preferred term Placebo (n = 364) Adjunctive lacosamide
200 mg/day (n = 270) 400 m
Memory impairment 6 (1.6) 3 (1.1) 7 (1.5
Cognitive disorder 1 (0.3) 1 (0.4) 10 (2.1
Confusional state 3 (0.8) 0 (0) 7 (1.5
Disturbance in attention 2 (0.5) 0 (0) 5 (1.1
Mental impairment 0 (0) 0 (0) 2 (0.4
MedDRA, Medical Dictionary for Regulatory Activities.
For each TEAE, data are presented as n (%) of patients experiencing the TEAE at least once.
a Data presented for TEAEs potentially related to cognition with an incidence of ≥1% during3.10. Cardiac events
The placebo-adjusted mean maximum increase in PR interval with
lacosamide was 1.5 ms for 200 mg/day, 3.1 ms for 400 mg/day, and
4.5ms for 600mg/day. Four lacosamide-treated patients had a nonseri-
ous TEAE of ﬁrst degree atrioventricular (AV) block (two patients
receiving 200 mg/day, one receiving 400 mg/day, and one receiving
600 mg/day). No patient in the placebo group experienced ﬁrst degree
AV block. There were no ﬁndings of second degree or higher AV block.
4. Discussion
The analyses reported here were performed by pooling data from
three pivotal double-blind, placebo-controlled trials of adjunctive
lacosamide in adults with POS to determine whether any new safety
trends or safety risks associated with lacosamide treatment could be
detected in a larger patient population. Although the majority of
the 1308 patients in this pooled dataset reported at least one TEAE,
most TEAEs were mild or moderate in intensity. Furthermore,
three-quarters of patients who were randomized and 96% of those
who completed the double-blind trials were enrolled in the subsequent
lacosamide open-label extensions, suggesting that most patients and
physicians found the tolerability of lacosamide to be favorable. The
most common drug-associated TEAEs were typically related to nervous
and gastrointestinal systems and generally appeared to be dose-related.
For all lacosamide doses combined, dizziness, nausea, and diplopia
occurred with an incidence of ≥10%.
Among all patients who received lacosamide, no individual SAE
occurred in ≥1% of patients; this is consistent with what was noted in
each of the individual trials [10–12]. The most frequently reported
SAEs (≥1% of patients in any lacosamide dose group) were convulsion,
dizziness, and nystagmus. Dizziness and nystagmus were reported as
SAEs only with the highest dose (600mg/day), and convulsion general-
ly occurred with a similar incidence for placebo and lacosamide.
A dose relationship was apparent for all of the common TEAEs
considered to be associated with lacosamide in these pooled analyses,
similar to most other AEDs. Themost frequently reported TEAEs associ-
ated with adjunctive lacosamide treatment occurred with a notably
lower incidence during themaintenance phase than during the titration
phase. This may be due to how the data were recorded with onset oc-
curring in the titration phase but continuing during the maintenance
phase being only recorded as having onset in the titration phase. How-
ever, this result may also be related, at least in part, to the design of the
trials, which employed forced titration to a predeﬁned target dose and
required concomitant AEDs to be maintained at a stable dose [10–12].
These pooled analyses align with a recent meta-analysis of randomized
controlled trials of lacosamide in patients with POS, neuropathic pain,
migraine, ﬁbromyalgia, or knee osteoarthritis [25], and considered to-
gether, these data suggest that some patients may be most susceptible
to AEs during dose adjustment. Flexible dosing of AEDs including
lacosamide, as well as adjustment of existing AED regimens, is routinelytrolled clinical trials of lacosamide for the adjunctive treatment of adultswith partial-onset
g/day (n = 471) 600 mg/day (n = 203) All doses of lacosamide (n = 944)
) 12 (5.9) 22 (2.3)
) 4 (2.0) 15 (1.6)
) 7 (3.4) 14 (1.5)
) 4 (2.0) 9 (1.0)
) 2 (1.0) 4 (0.4)
the treatment phase in any lacosamide dose group.
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patient response differs from the ﬁxed-dose allocation and stable
background AEDs used in these clinical trials. Therefore, the higher inci-
dence of TEAEs during AED titration in the present study may be better
managed in clinical practice.
A dose-dependent increase in discontinuations due to TEAEs was
observed, with dizziness reported as the most common cause. Post hoc
analyses from these pivotal trials, as well as studies conducted in a
real-life setting, suggest a potential for improved tolerability when
lacosamide was added to an AED regimen that did not include sodium
channel-blocking AEDs, especially at higher lacosamide dosages
[23,26–28]. The post hoc analysis of TEAEs leading to discontinuation
according to concomitant AED use reported here is difﬁcult to interpret
because the sample size for concomitant AED groups was unbalanced,
concomitant AED groupings were not mutually exclusive, and the ma-
jority of patients (84%) were taking at least two concomitant AEDs.
However, the trend of the ﬁndings suggests that nervous system
TEAEs occurred more frequently for patients on concomitant sodium
channel blockers.
Included in this detailed assessment of lacosamide safety was an
evaluation of TEAEs that have been identiﬁed to be of particular interest
in patients taking AEDs [29–32]. Similar to other AEDs, the use of
adjunctive lacosamide treatment was associated with TEAEs related to
the nervous system, and this was found predominantly during the
titration phase. However, no trends in the nature or frequency of
seizure-related TEAEs, or TEAEs of rash, psychiatric disturbances,weight
change, or changes in clinical chemistry values or vital signswere found.
Selected TEAEs potentially related to cognitive impairment were
analyzed post hoc, and the incidence was similar between lacosamide
dosages of 200 mg/day and 400 mg/day and placebo. These overall
observations from selected TEAEs are generally consistent with a retro-
spective study assessing the impact of lacosamide and other AEDs
(topiramate and lamotrigine) on cognition using EpiTrack® in patients
with epilepsy [33]. This naturalistic study indicated that the cognitive
side effect proﬁle of lacosamide was comparable to that of lamotrigine,
whereas topiramate performed worse than both lacosamide and
lamotrigine, as indicated by both subjective and objective measures
[33]. With respect to cardiac events, a small, dose-related increase in
PR interval was observed with adjunctive lacosamide treatment, but
this did not lead to clinically signiﬁcant delay in cardiac conduction. A
full review of cardiac safety data in patients with POS has been conduct-
ed and published elsewhere [34]. Based on all available data, it is recom-
mended that lacosamide should continue to be used with caution in
patients with known conduction problems or sodium channelopathies,
patients on drugs known to induce PR interval prolongation, or those
with severe cardiac disease such as myocardial ischemia, heart failure,
or structural heart disease; the US but not the EU label recommends
that in such patients, an ECG should be obtained before beginning
lacosamide, and after lacosamide is titrated to steady-state, mainte-
nance dose is recommended [1,2].
Overall, a priori and post hoc safety analyses provide a more detailed
description of the lacosamide safety proﬁle across the dose range of
200–600 mg/day in adults with epilepsy and uncontrolled POS, most
of whom were taking 2–3 concomitant AEDs. The results of these
analyses conﬁrm and extend earlier ﬁndings from the individual trials
that lacosamide was generally well tolerated, with the best tolerability
observed for the approved dose range (200–400 mg/day).
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